Traditional Chinese medicine composition for relieving immune checkpoint inhibitor related cardiotoxicity and application thereof

Through the combination of traditional Chinese medicine compositions such as pine, raw astragalus, and red peony root, the treatment problem of cardiotoxicity related to immune checkpoint inhibitors is solved, and the cardiac function and quality of life are significantly improved, achieving safe and efficient relief effects.

CN119074842APending Publication Date: 2024-12-06NINGBO FIRST HOSPITAL
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202411198677.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-29
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Cardiac toxicity related to immune checkpoint inhibitors leads to serious cardiovascular diseases such as myocarditis and arrhythmias. The current treatment effect is poor, and the long-term survival quality of patients is affected.

Method used

A Chinese medicine composition is adopted, including pine, raw astragalus, red peony, lowering fragrance, citrus aurantium, cypress aurantium, madder and roasted licorice, which can nourish the body by invigorating qi and promoting blood circulation, nourishing the heart, regulating qi and dispersing blood stasis, removing blood stasis and stopping bleeding, etc., to form a tonic The combination effect of Qi promoting Qi and promoting blood circulation is used to alleviate cardiotoxicity.

Benefits of technology

It significantly improves the patient's heart function and quality of life, reduces cardiotoxic symptoms, and has no obvious side effects, which is safe and effective.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005017251950000061
    Figure BDA0005017251950000061
  • Figure BDA0005017251950000082
    Figure BDA0005017251950000082
Patent Text Reader

Abstract

The invention discloses a traditional Chinese medicine composition for relieving immune checkpoint inhibitor related cardiotoxicity and application thereof. The traditional Chinese medicine composition belongs to the technical field of traditional Chinese medicines and comprises the following components in parts by mass: 6-15 parts of rhizoma nardostachyos, 25-50 parts of raw radix astragali, 10-25 parts of radix paeoniae rubra, 6-10 parts of lignum dalbergiae odoriferae, 5-15 parts of fructus aurantii, 5-15 parts of rhizoma cyperi, 10-20 parts of radix rubiae and 1-5 parts of honey-fried licorice root. The traditional Chinese medicine composition provided by the invention has the effects of tonifying qi, activating blood and nourishing heart, and is suitable for relieving cardiotoxicity caused by an immune checkpoint inhibitor. The clinical curative effect of the immune checkpoint inhibitor can be improved, the life quality of a patient is improved, and safety and no side effect are achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of traditional Chinese medicines, and in particular to a traditional Chinese medicine composition for alleviating immune checkpoint inhibitor-associated cardiotoxicity and an application thereof. Background Art

[0002] The development of immune checkpoint inhibitors (ICIs) has provided a new treatment option for various cancers. Specifically, ICIs are monoclonal antibodies (anti-PD-1, anti-PD-L1, anti-CTLA-4, and anti-LAG-3) that are used to directly target inhibitory receptors on cancer cells and T cells and antigen-presenting cells. Therefore, they are able to enhance the ability of T cells to target and eliminate cancer cells without being inhibited by checkpoint proteins. However, this progress has been accompanied by a series of cardiotoxic adverse events, such as myocarditis, pericardial disease, arrhythmias, myocardial infarction, and even non-inflammatory left ventricular function impairment. Some can manifest as acute, rapidly progressing within a few days or weeks after ICI treatment; some can manifest as chronic diseases, which can lead to a significant increase in cardiovascular morbidity and mortality in the long term. The incidence of ICIs-related cardiotoxicity is estimated to be more than 5%, and the risk is extremely high. If ICIs-related cardiotoxicity occurs, Western medicine currently mainly uses glucocorticoids to reduce myocardial inflammatory response, statins to delay the progression of coronary heart disease, and basic anti-heart failure drugs to inhibit heart failure caused by inflammation. However, the degree of relief of the above-mentioned cardiotoxicity is still not obvious, and it often coexists with cancer patients for a long time, such as the continuous increase of myocardial injury markers (troponin, myocardial enzyme spectrum, etc.), and the cardiac function status (activity tolerance, brain natriuretic peptide level, left ventricular ejection fraction level, etc.) cannot be significantly improved.

[0003] Therefore, it is of great significance to develop drugs with fewer side effects to alleviate immune checkpoint inhibitor-associated cardiotoxicity. Summary of the invention

[0004] The purpose of the present invention is to provide a safe and effective drug for alleviating immune checkpoint inhibitor-related cardiotoxicity.

[0005] To achieve the above objectives, the first aspect of the present invention provides a traditional Chinese medicine composition for alleviating immune checkpoint inhibitor-associated cardiotoxicity, which comprises the following components, by weight: 6-15 parts of Nardostachys grandiflora, 25-50 parts of raw Astragalus, 10-25 parts of red peony root, 6-10 parts of Dalbergia odorifera, 5-15 parts of Citrus aurantium, 5-15 parts of Cyperus rotundus, 10-20 parts of Rubia cordifolia, and 1-5 parts of roasted Licorice root.

[0006] Compared with the prior art, the present invention has the beneficial effects that most clinical tumor patients are in a state of deficiency of the body and excess of pathogenic factors. Most of the patients with cardiac toxicity are in a state of deficiency of the body and excess of pathogenic factors. Insufficiency of the body's vital energy is the cause of the disease, and stagnation of qi and blood stasis are the direct causes of the disease. Qi deficiency and blood stasis are the main pathological mechanisms. Based on this, the present invention provides a Chinese medicine composition for invigorating qi, activating blood circulation and nourishing the heart. In the Chinese medicine composition provided by the present invention, sweet pine is the main medicine, which is pungent, sweet, warm, and enters the spleen and stomach meridians. It has the effects of warming the middle and dispersing cold, aromatic and invigorating the mind, invigorating the spleen and stimulating the appetite, regulating qi and relieving pain, and is mainly used to treat abdominal distension and pain, loss of appetite, insufficient heart blood, epilepsy, phlegm and syncope, etc. Sweet pine has a fragrant smell, is good at invigorating the mind, can wander around, can be used for the meridians of the liver and spleen, and can relieve the stagnation of long-term diseases, promote qi and relieve depression, and nourish the heart and calm the mind. Astragalus and red peony root are the ministerial medicines. Astragalus is sweet, slightly warm, enters the spleen and lung meridians, replenishes qi and consolidates the exterior, supports toxins and discharges pus, promotes urination, and promotes tissue regeneration. Red peony root is bitter, slightly cold, belongs to liver meridian, clears away heat and cools blood, disperses blood stasis and relieves pain. The present invention uses Radix Astragali and Radix Paeoniae Rubra as ministerial drugs, and achieves the effect of invigorating qi, promoting qi and activating blood circulation. Fructus Aurantii Immaturus, Rhizoma Cyperi, Radix Rubiae, Radix Glycyrrhizae Preparata are adjuvant drugs, Fructus Aurantii Immaturus is bitter, pungent, sour, slightly cold, belongs to spleen and stomach meridian, soothes liver and harmonizes stomach, regulates qi and relieves pain, eliminates stagnation and resolves stagnation. It is used for chest and flank qi stagnation, fullness and pain, indigestion, phlegm and fluid retention, gastroptosis, prolapse of the anus, and prolapse of the uterus. Fructus Cyperi is pungent, slightly bitter, slightly sweet, flat, belongs to liver, spleen, triple burner meridian, soothes liver and relieves depression, regulates qi and relieves chest tightness, regulates menstruation and relieves pain. It is used for flank pain, abdominal pain caused by liver depression and qi stagnation, irregular menstruation, dysmenorrhea, breast distending pain, abdominal pain caused by spleen and stomach qi stagnation, etc. Rubia cordifolia is bitter and cold in nature, and it enters the liver meridian, cools blood and removes blood stasis, stops bleeding and dysmenorrhea, and is used for hematemesis, epistaxis, metrorrhagia, traumatic bleeding, blood stasis blocking amenorrhea, arthralgia, and swelling and pain caused by falls. Radix Glycyrrhizae Preparata is sweet in nature, flat, enters the heart, lung, spleen, and stomach meridians, invigorates the spleen and replenishes qi, replenishes qi and restores the pulse, and is used for spleen and stomach weakness, fatigue, palpitations, and pulse knots. Radix Glycyrrhizae Preparata replenishes qi and restores the pulse, and agitates the blood vessels. In the present invention, Radix Glycyrrhizae Preparata and Fructus Aurantii Immaturus, Rhizoma Cyperi, and Rhizoma Cyperi are adjuvants in total, and they are used to replenish qi and restore the pulse, and the merit of promoting qi, activating blood circulation and removing blood stasis is performed together. In the present invention, Radix Dalbergiae Odoriferae is a making drug, and Radix Dalbergiae Odoriferae is pungent in nature, warm, enters the liver and spleen meridians, removes blood stasis and stops bleeding, regulates qi and relieves pain, and is used for chest tightness and pain, epigastric and hypochondriacal stinging, and external treatment of bleeding caused by falls. The present invention uses Radix Dalbergiae Odoriferae as a making drug, and the function of promoting qi and activating blood circulation is used, and all medicines are directly directed to the diseased area. Through the above-mentioned drug compatibility and clinical research, the Chinese medicine composition provided by the present invention has an excellent alleviating effect on the cardiotoxicity caused by immune checkpoint inhibitors, can effectively improve the quality of life of patients, and is safe and has no side effects.

[0007] Preferably, the Chinese medicine composition comprises the following components in parts by mass: 6-10 parts of Nardostachys grandiflora, 25-30 parts of raw Astragalus, 10-15 parts of red peony root, 6-8 parts of Dalbergia odorifera, 10-15 parts of Fructus Aurantii Immaturus, 9-10 parts of Cyperus rotundus, 10-15 parts of Rubia cordifolia, and 1-3 parts of roasted Licorice root.

[0008] Preferably, the Chinese medicine composition comprises the following components by mass: 6 parts of Nardostachys grandiflora, 25 parts of raw Astragalus, 15 parts of red peony root, 6 parts of Dalbergia odorifera, 10 parts of Fructus Aurantii Immaturus, 9 parts of Cyperus rotundus, 15 parts of Rubia cordifolia, and 3 parts of Radix Glycyrrhizae Preparata.

[0009] Furthermore, the second aspect of the present invention provides a use of the traditional Chinese medicine composition described in the first aspect in the preparation of a drug for treating and alleviating immune checkpoint inhibitor-related cardiotoxicity.

[0010] Furthermore, the third aspect of the present invention provides a pharmaceutical preparation for alleviating immune checkpoint inhibitor-related cardiotoxicity, wherein the pharmaceutical preparation is prepared from the traditional Chinese medicine composition of the first aspect and a pharmacologically acceptable carrier.

[0011] The pharmaceutical preparation provided by the present invention includes, in addition to the effective pharmaceutical ingredients, carriers such as excipients and auxiliary materials permitted for use in pharmaceutical preparations. The function of these carriers is to process the effective ingredients into preparations and to transport the effective ingredients to the site of action in the body.

[0012] Preferably, the dosage form of the pharmaceutical preparation is an oral dosage form.

[0013] Preferably, the pharmaceutical preparation is selected from any one of a decoction, honey pills, water-honey pills, water pills, granules, capsules, tablets, oral liquid or syrup.

[0014] When the Chinese medicine composition provided by the present invention is in the form of a pharmaceutical preparation, such as a solid, semi-solid or liquid form, these pharmaceutical preparations, in addition to containing active ingredients, are also mixed with organic or inorganic excipients and auxiliary materials, and are suitable for gastrointestinal absorption of drugs. The aforementioned excipients or auxiliary materials include talc, water, glucose, lactose, gum arabic, gelatin, mannitol, starch, magnesium trisilicate, corn starch, keratin and any carrier that can be used to prepare solid, semi-solid or liquid preparations. In addition, auxiliary agents such as stabilizers, thickeners, colorants, flavoring agents, etc. can also be used.

[0015] When the pharmaceutical preparation provided by the present invention is a tablet or capsule, the auxiliary material is selected from corn starch, dicalcium phosphate, sucrose, sorbitol, talc, fatty acid, magnesium stearate, gum, or other pharmaceutical diluents, or the compound contains a substantially uniform mixture of the Chinese medicine composition of the present invention or its non-toxic pharmaceutical salt.

[0016] When the pharmaceutical preparation provided by the present invention is an oral liquid, its specific dosage form includes aqueous solution, syrup, water or oil suspension, emulsion, and the relevant auxiliary materials are selected from any one or more of sodium carboxymethyl cellulose, tragacanth gum, gum arabic, dextran, gelatin, and edible oil.

[0017] Regarding the route of administration: The route of administration of the pharmaceutical preparation provided by the present invention is gastrointestinal administration, which can be achieved by oral administration or enema.

[0018] Regarding dosage: the dosage should be selected according to the specific patient's age, weight, health condition, course of treatment, individual differences, dosage form, and route of administration. The Chinese medicine composition provided by the present invention can be used alone or in combination with glucocorticoids, statins, or in combination with other therapeutic compounds according to actual conditions. DETAILED DESCRIPTION

[0019] In order to make the above-mentioned purposes, features and advantages of the present invention more obvious and easy to understand, the specific embodiments of the present invention are described in detail below. It should be noted that the following embodiments are only used to illustrate the implementation method and typical parameters of the present invention, and are not used to limit the parameter range described in the present invention. Reasonable changes derived therefrom are still within the scope of protection of the claims of the present invention.

[0020] It should be noted that the endpoints and any values ​​of the ranges disclosed in this article are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of each range, the endpoint values ​​of each range and the individual point values, and the individual point values ​​can be combined with each other to obtain one or more new numerical ranges, and these numerical ranges should be regarded as specifically disclosed in this article.

[0021] Unless otherwise defined, all terms, symbols and other scientific terms used herein are intended to have the same meaning as those commonly understood by those skilled in the art to which the present invention belongs. In some cases, terms with conventionally understood meanings are defined herein for the purpose of clarification or ease of reference, and such definitions herein should not be construed as indicating significant differences from conventional understandings in the art. The technical methods described or cited herein are generally well understood by those skilled in the art and are adopted by conventional methods. Unless otherwise stated, the use of commercially available kits, reagents and instruments is carried out in accordance with the protocols and parameters given by the manufacturer.

[0022] As described in the background technology, existing drugs, such as relieving cardiotoxicity caused by immune checkpoint inhibitors, often have defects such as poor effect and prognosis. Based on this, the specific embodiment of the present invention provides a Chinese medicine composition for relieving cardiotoxicity associated with immune checkpoint inhibitors with small side effects and good effects. By mass, the Chinese medicine composition provided by the present invention includes the following components: 6 to 15 parts of nard, 25 to 50 parts of raw astragalus, 10 to 25 parts of red peony root, 6 to 10 parts of dalbergia odorifera, 5 to 15 parts of fructus aurantii, 5 to 15 parts of cyperus, 10 to 20 parts of madder, and 1 to 5 parts of licorice.

[0023] Nardostachys galanga is often used to treat cardiovascular diseases and digestive system diseases. The Chinese patent medicine made from Nardostachys galanga has a certain effect in treating cardiovascular diseases such as arrhythmia. Nardostachys galanga can nourish the heart and blood, calm the mind and stabilize the spirit. It is suitable for the elderly and the weak, or the body is weak, or the long-term illness leads to insufficient qi and blood, and the mind is not nourished. In clinical practice, Nardostachys galanga is mostly used as a guide drug to relieve depression and resolve knots, soothe the liver and regulate the spleen, and make the monarch and minister drugs nourish without stagnation. The specific implementation method of the present invention is the first time that Nardostachys galanga is used as the monarch drug, and Astragalus membranaceus and red peony root are compatible to replenish qi, promote qi and activate blood circulation, and are minister drugs; with the help of Citrus aurantium, Cyperus rotundus, Rubia cordifolia, and Glycyrrhiza uralensis, it strengthens the power of replenishing qi and restoring pulse, promoting qi, activating blood circulation and removing blood stasis; the guide drug is Dalbergia odorifera, which promotes qi and activates blood circulation, and leads all the drugs directly to the diseased area. The whole prescription plays the role of replenishing qi, activating blood circulation and nourishing the heart. This prescription is derived from the classic prescription Buyang Huanwu Decoction, which contains earthworms. Since earthworms have a fishy smell, patients will experience obvious gastrointestinal symptoms after taking them. For tumor patients, their digestive function is poor, so earthworms are not suitable for use. Therefore, the specific implementation of the present invention removes earthworms, a blood-activating drug, from the original prescription and uses madder instead.

[0024] Example 1

[0025] Decoction preparation

[0026] By weight, 6 parts of Nardostachys grandiflora, 25 parts of raw Astragalus, 15 parts of red peony root, 6 parts of Dalbergia odorifera, 10 parts of Citrus aurantium, 9 parts of Cyperus rotundus, 15 parts of Rubia cordifolia, and 3 parts of Radix Glycyrrhizae Preparata were taken. The above medicinal materials were soaked in water for half an hour, boiled over high heat, and then simmered for 30 minutes over low heat, the first decoction was taken, and water was added to decoct for 20 minutes, the second decoction was taken, and the two decoctions were mixed to prepare a decoction, and the relationship between the weight of the medicinal materials and the amount of the decoction was about 4g / mL.

[0027] Example 2

[0028] Granule preparation

[0029] According to the mass ratio, take 15 parts of Nardostachys grandiflora, 50 parts of raw Astragalus, 25 parts of red peony root, 10 parts of Dalbergia odorifera, 15 parts of Citrus aurantium, 15 parts of Cyperus rotundus, 20 parts of Rubia cordifolia, and 5 parts of Radix Glycyrrhizae. Add water to the above medicinal materials to submerge the medicinal materials, soak for 3 hours, heat to boiling, decoct for 0.5 hours, and take the decoction. Decoction the residue twice according to the law, and combine the decoctions. After filtering, evaporate and concentrate (1:1), add 1.5 times the amount of ethanol after cooling, mix well, leave overnight, take the supernatant, wash the precipitate with a small amount of 50% ethanol, combine the washing liquid with the filtrate, recover the ethanol under reduced pressure, concentrate, cool and stand, filter, vacuum and low-temperature concentrate to a thick paste, the specific gravity of the thick paste is 1.33, spray dry and pass through a 300-mesh sieve, and make granules to obtain granules.

[0030] Example 3

[0031] Animal pharmacology experiments

[0032] Experimental animals: 30 healthy male BALB / c mice aged 6 weeks were randomly divided into two groups: control group, model group and treatment group, with 10 mice in each group. They were raised in the Experimental Animal Center of Ningbo University in strict accordance with SPF grade standards.

[0033] Animal model establishment: The mice were divided into control group, model group and treatment group, with 10 mice in each group. The control group was treated with intraperitoneal injection of 100 μL PBS buffer twice a week for 3 weeks; the model group was treated with intraperitoneal injection of 10 mg kg humanized PD-1 monoclonal antibody Trelizumab (Beijing BeiGene) -1 , twice a week for 3 consecutive weeks; the treatment group was injected with 10 mg kg of humanized PD-1 monoclonal antibody tislelizumab -1 , twice a week for 3 consecutive weeks, and at the same time, 0.2 ml of the decoction prepared in Example 1 was given by intragastric administration every day.

[0034] General status observation and index measurement: On the 17th day of modeling, mice in each group underwent two-dimensional echocardiography. The mice were skinned in the chest area, anesthetized by inhalation of isoflurane, and placed in a supine position. M-mode images were displayed at the maximum left ventricular diameter in the long axis section of the left ventricle beside the sternum, and LVEF was analyzed. All measurement results were averaged over three consecutive cardiac cycles. Then all mice were killed, the chest was opened, and blood-borne cardiac injury indicators (BNP, aTnI) were tested.

[0035] Statistical analysis: SPSS 18.0 software was used for data analysis. Measurement data that conformed to normal distribution were expressed as x±s. Independent sample t test was used for comparison between two groups, and one-way analysis of variance was used for comparison between multiple groups. Two-sided test, test level α = 0.05.

[0036] The experimental results are shown in Table 1:

[0037] Table 1

[0038]

[0039] *, comparison between model group and control group; *, comparison between treatment group and model group.

[0040] As shown in Table 1, compared with the control group, the cardiac function indexes (LVEF, aTnI and Pro-BNP) in the model group were significantly impaired (P < 0.05); compared with the model group, the cardiac ultrasound indexes (LVEF), aTnI and Pro-BNP in the treatment group were significantly improved, and the difference was statistically significant (P < 0.05).

[0041] Example 4

[0042] Clinical trials

[0043] A total of 60 patients with ICIs-related cardiotoxicity who were hospitalized in the First Affiliated Hospital of Ningbo University from July 2020 to June 2024 were randomly divided into a treatment group and a control group, with 30 cases in each group. The demographic data, clinical data, and laboratory indicators of the subjects were collected, including age, gender, BMI, smoking history, history of hypertension, history of diabetes, history of hyperlipidemia, aTnI, LDL-C, HDL-C, ALT, AST, albumin, and creatinine. There was no significant difference in the baseline data between the two groups (P>0.05), and they were comparable.

[0044] The diagnostic criteria refer to the diagnostic criteria for immunotherapy-related cardiovascular toxicity in the "Clinical Practice Guidelines for Oncology Cardiology 2023" of the Chinese Society of Clinical Oncology.

[0045] Diagnostic criteria:

[0046] (1) Clinical symptoms and signs

[0047] The clinical manifestations of most patients with cardiac irAEs caused by ICIs are not particularly different from those of the corresponding heart diseases. Early symptoms are mainly palpitations and chest pain, and severe cases may experience dyspnea, wheezing, syncope, etc. Physical examination can show patients with arrhythmias (atrial premature beats, ventricular premature beats, atrioventricular block, etc. are more common), edema of both lower limbs, etc. If symptoms of heart failure occur, there may be signs such as distended neck veins, moist rales in both lungs, and enlarged liver dullness.

[0048] (2) Auxiliary examination

[0049] 1) The gold standard for diagnosis is endomyocardial biopsy.

[0050] 2) Cardiac MRI is of great value in the diagnosis of myocarditis, with the typical manifestation being patchy enhancement of the myocardium on delayed gadolinium enhancement scans.

[0051] 3) Echocardiogram: In 2014, the expert consensus of the American Society of Ultrasound and the European Society of Cardiovascular Imaging defined cancer treatment-related cardiac dysfunction as: regardless of whether there are clinical symptoms, the left ventricular ejection fraction (LVEF) decreases by 10% from the baseline or the absolute value is less than 53%, and the above results are still found when repeated examinations are performed 2 to 3 weeks later.

[0052] 4) Electrocardiogram: For patients with myocarditis, ST changes are common in electrocardiograms, including mild ST segment shift and T wave inversion. Patients with acute pericarditis may have extensive ST segment elevation outside of lead aVR, and a few may have pathological Q waves. Various types of arrhythmias may occur, especially ventricular arrhythmias and atrioventricular block.

[0053] 5) Myocardial injury indicators: cardiac troponin and myocardial enzyme spectrum are often used to diagnose acute myocardial infarction, and abnormalities can occur before the left ventricular ejection fraction decreases. B-type natriuretic peptide (BNP): Elevated BNP or NT-proBNP can detect subclinical cardiac toxicity caused by ICIs in advance, especially diastolic dysfunction.

[0054] The syndrome differentiation standard refers to the Qi deficiency and blood stasis heart failure syndrome type in the "Guidelines for Clinical Research of New Chinese Medicines (Trial)". Main symptoms: palpitations and shortness of breath, chest and flank pain, exposed blue veins in the front part, lumps under the flank, and edema of the lower limbs. Secondary symptoms: dull complexion, bluish lips and nails. The tongue is purple or has petechiae and ecchymosis, and the pulse is sluggish or intermittent. The main symptoms and secondary symptoms, combined with the tongue and pulse, can be diagnosed.

[0055] Inclusion criteria: cancer patients treated with ICIs and not receiving other chemoradiotherapy; aged between 18 and 70 years old; with clear ICIs-related cardiotoxicity.

[0056] Exclusion criteria: patients with heart failure or myocardial damage caused by underlying heart disease; patients with myocardial damage or heart failure caused by infection, abnormal renal function, pulmonary embolism, etc.; eGFR < 30ml / min / 1.73m 2 ; Severe liver damage, biliary cirrhosis and cholestasis; symptomatic hypotension (systolic blood pressure <90 mmHg); history of angioedema; pregnant and lactating women; patients with incomplete data.

[0057] Treatment:

[0058] (1) The control group received perindopril [Servier (Tianjin) Pharmaceutical Company, batch number: H20034053, specification: 4 mg / tablet], taken orally in the morning on an empty stomach, with an initial dose of 2 mg each time. After the patients tolerated it for 2 weeks, the dose was increased to 4 mg each time. The control group received metoprolol tartrate tablets (trade name: Betaloc, AstraZeneca Pharmaceuticals Co., Ltd., batch number: H32025392, specification: 25 mg / tablet), with an initial dose of 6.25 mg twice a day. The dose was gradually increased to 100 mg twice a day (heart rate not less than 55 beats / min) as long as the heart rate was tolerated.

[0059] (2) The treatment group took the decoction prepared in Example 1 orally in the morning and evening on the basis of the control group, divided into two doses, about 200 mL each time, for a total of 4 weeks.

[0060] SPSS 18.0 statistical software was used for statistical description and analysis. The patient's demographic data, clinical data, and laboratory indicators were described by the rate, composition ratio, etc. The measurement data were in accordance with the normal distribution using the t test, and those that were not in accordance with the normal distribution using the rank sum test; the enumeration data were described using frequency and percentage, and the binary data were compared between groups using the χ2 test. P<0.05 was considered statistically significant.

[0061] The test results are shown in Table 2:

[0062]

[0063] As shown in Table 2, compared with Western medicine alone, the cardiac ultrasound indices (LVEF, LVDd) and Pro-BNP in the treatment group (TCM + Western medicine) were significantly improved after medication, with statistically significant differences (P < 0.05). Although there was no statistically significant difference in LVDs between the two groups after treatment, the improvement in the treatment group was more obvious.

[0064] Safety evaluation indicators: No obvious adverse reactions (such as liver and kidney damage, abnormal coagulation function, etc.) were observed in both groups.

[0065] In summary, the Chinese medicine compound provided by the present invention can improve ICIs-related cardiotoxicity in cancer patients, significantly improve the patients' cardiac function and activity tolerance, and has no obvious adverse reactions, and has good safety.

[0066] Although the disclosure is disclosed as above, the protection scope of the disclosure is not limited thereto. Those skilled in the art can make various changes and modifications without departing from the spirit and scope of the disclosure, and these changes and modifications will fall within the protection scope of the present invention.

Claims

1. A Chinese medicine composition for alleviating immune checkpoint inhibitor-related cardiotoxicity, characterized in that: The composition comprises the following components by weight: 6-15 parts of nardostachys galanga, 25-50 parts of raw astragalus, 10-25 parts of red peony root, 6-10 parts of dalbergia odorifera, 5-15 parts of fructus aurantii, 5-15 parts of cyperus rotundus, 10-20 parts of madder root and 1-5 parts of roasted liquorice root.

2. The Chinese medicine composition according to claim 1, characterized in that The composition comprises the following components by weight: 6-10 parts of nardostachys galanga, 25-30 parts of raw astragalus, 10-15 parts of red peony root, 6-8 parts of dalbergia odorifera, 10-15 parts of fructus aurantii, 9-10 parts of cyperus rotundus, 10-15 parts of madder root, and 1-3 parts of roasted liquorice root.

3. A Chinese medicine composition according to claim 1, characterized in that: The invention comprises the following components by weight: 6 parts of rhizoma naringii, 25 parts of raw astragalus, 15 parts of red peony root, 6 parts of dalbergia odorifera, 10 parts of fructus aurantii, 9 parts of cyperus rotundus, 15 parts of madder root and 3 parts of roasted liquorice.

4. Use of the traditional Chinese medicine composition according to any one of claims 1 to 3 in the preparation of a drug for treating and alleviating immune checkpoint inhibitor-related cardiotoxicity.

5. A pharmaceutical preparation for alleviating immune checkpoint inhibitor-associated cardiotoxicity, characterized in that: The pharmaceutical preparation is prepared from the Chinese medicine composition according to any one of claims 1 to 3 and a pharmacologically acceptable carrier.

6. The pharmaceutical preparation according to claim 5, characterized in that The dosage form of the pharmaceutical preparation is an oral dosage form.

7. The pharmaceutical preparation according to claim 6, characterized in that The pharmaceutical preparation is selected from any one of decoction, honey pill, water-honey pill, water pill, granule, capsule, tablet, oral liquid or syrup.

Citation Information

Patent Citations

  • Traditional Chinese medicine for treating cerebral arteriosclerosis

    CN104784402A